Below are the most recent publications written about "Pyrazines" by people in Profiles.
-
Sugiki T, Yoshida T, Tsukamoto M, Miyanishi K, Kagawa A, Miura N, Ura T, Fukazawa J, Hatanaka Y, Murata T, Fujiwara T, Kitagawa M, Morita Y, Sakai-Kato K, Takakusagi Y, Tanaka N, Negoro M. Investigation of the functional hot-spot residues of an enzyme by real-time monitoring of the enzymatic reaction using NMR and computational approaches. Sci Rep. 2026 Jan 13; 16(1):5896.
-
Mita MM, Mita AC, Carver BJ, Shanahan JM, Mayes BA, Dufour PJ, Browning D, Anderson-Villaluz A, Petersen JS, Turnquist DJ, Cornelius P. A Phase 1 Safety Study of Evexomostat (SDX-7320) in Patients with Late-Stage Cancer: An Antiangiogenic, Insulin-Sensitizing Drug Conjugate Targeting METAP2. Cancer Res Commun. 2025 Jun 01; 5(6):1008-1017.
-
Sugiki T, Ito A, Hatanaka Y, Tsukamoto M, Murata T, Miyanishi K, Kagawa A, Fujiwara T, Kitagawa M, Morita Y, Negoro M. Real-time monitoring of enzyme-catalyzed phosphoribosylation of anti-influenza prodrug favipiravir by time-lapse nuclear magnetic resonance spectroscopy. NMR Biomed. 2023 05; 36(5):e4888.
-
Holubar M, Subramanian A, Purington N, Hedlin H, Bunning B, Walter KS, Bonilla H, Boumis A, Chen M, Clinton K, Dewhurst L, Epstein C, Jagannathan P, Kaszynski RH, Panu L, Parsonnet J, Ponder EL, Quintero O, Sefton E, Singh U, Soberanis L, Truong H, Andrews JR, Desai M, Khosla C, Maldonado Y. Favipiravir for Treatment of Outpatients With Asymptomatic or Uncomplicated Coronavirus Disease 2019: A Double-Blind, Randomized, Placebo-Controlled, Phase 2 Trial. Clin Infect Dis. 2022 11 30; 75(11):1883-1892.
-
Fantasia HC, Morse BL. Voxelotor for the Treatment of Sickle Cell Disease. Nurs Womens Health. 2020 Jun; 24(3):233-237.
-
Parikh KS, Doerfler S, Shelburne N, Kennedy K, Whitson J, Dahhan T, Fortin T, Rajagopal S. Experience in Transitioning From Parenteral Prostacyclins to Selexipag in Pulmonary Arterial Hypertension. J Cardiovasc Pharmacol. 2020 04; 75(4):299-304.
-
Ormond L, Liu P, Matuszewski S, Renzette N, Bank C, Zeldovich K, Bolon DN, Kowalik TF, Finberg RW, Jensen JD, Wang JP. The Combined Effect of Oseltamivir and Favipiravir on Influenza A Virus Evolution. Genome Biol Evol. 2017 07 01; 9(7):1913-1924.
-
Bank C, Renzette N, Liu P, Matuszewski S, Shim H, Foll M, Bolon DN, Zeldovich KB, Kowalik TF, Finberg RW, Wang JP, Jensen JD. An experimental evaluation of drug-induced mutational meltdown as an antiviral treatment strategy. Evolution. 2016 11; 70(11):2470-2484.
-
Harrington BK, Gardner HL, Izumi R, Hamdy A, Rothbaum W, Coombes KR, Covey T, Kaptein A, Gulrajani M, Van Lith B, Krejsa C, Coss CC, Russell DS, Zhang X, Urie BK, London CA, Byrd JC, Johnson AJ, Kisseberth WC. Preclinical Evaluation of the Novel BTK Inhibitor Acalabrutinib in Canine Models of B-Cell Non-Hodgkin Lymphoma. PLoS One. 2016; 11(7):e0159607.
-
Ma F, Ye H, He HH, Gerrin SJ, Chen S, Tanenbaum BA, Cai C, Sowalsky AG, He L, Wang H, Balk SP, Yuan X. SOX9 drives WNT pathway activation in prostate cancer. J Clin Invest. 2016 05 02; 126(5):1745-58.